scholarly journals ASUPAN GIZI SEIMBANG TINGKATKAN IMUNITAS TUBUH SAAT PANDEMI COVID-19

2021 ◽  
pp. 503
Author(s):  
Alexander Halim Santoso ◽  
Sung Chian
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Severe Acute Respiratory Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
Close Contact ◽  
Severe Pneumonia ◽  
Learning System ◽  
World Health ◽  
Prevention Measures

Coronavirus Disease 2019 (COVID-19) is an infectious disease caused by the Coronavirus of the genus Severe Acute Respiratory Syndrome Human Corona virus (SARS-HCoV). Transmission of this disease occurs through close contact, especially through respiratory droplets when the patient coughs or sneezes. Most people with this disease recover spontaneously, but some experience a fatal worsening including organ failure, septic shock, pulmonary edema, severe pneumonia and acute respiratory distress syndrome (ARDS). Breaking the chain of transmission is the key to stopping the spread of this disease. The World Health Organization, WHO, said that there are three things that can be done to prevent the spread of this disease, namely by keeping a distance, not being in a closed room, and limiting mobilization (not gathering). Increasing body immunity by implementing a clean and healthy lifestyle (PHBS) such as consuming balanced nutrition, physical activity for at least 30 minutes a day, adequate rest, utilizing traditional health are part of disease prevention measures. Changes in the learning system during the pandemic made students easily exposed to various incorrect information. Efforts are needed to explain to students to increase students' awareness of the Covid-19 disease and its prevention stepsCoronavirus Disease 2019 (COVID-19) merupakan penyakit menular yang disebabkan oleh virus Coronavirus dari genus Severe Acute Respiratory Syndrome Human Coronarvirus (SARS-HCoV). Penularan penyakit ini terjadi kontak erat terutama melalui droplets saluran napas saat penderita batuk atau bersin. Sebagian besar penderita penyakit ini sembuh secara spontan, namun beberapa mengalami perburukan yang fatal mencakup gagal organ, syok septik, edema paru-paru, pneumonia berat dan sindrom gagal napas akut (acute respiratory distress syndrome/ARDS). Pemutusan rantai penularan merupakan kunci untuk menghentikan penyebaran penyakit ini. Organisasi Kesehatan Dunia, WHO, menyampaikan ada tiga hal yang dapat dilakukan untuk mencegah penyebaran penyakit ini yaitu dengan menjaga jarak, tidak berada dalam ruangan tertutup, dan membatasi mobilisasi (tidak berkumpul). Meningkatkan daya tahan tubuh dengan menerapkan pola hidup bersih sehat (PHBS) seperti mengonsumsi gizi seimbang, beraktivitas fisik minimal 30 menit sehari, istirahat yang cukup, memanfaatkan kesehatan tradisional merupakan bagian dari langkah-langkah pencegahan penyakit. Perubahan sistem pembelajaran selama Pandemi berlangsung membuat siswa mudah terpapar dengan berbagai informasi yang tidak benar. Diperlukan upaya penjelasan pada para siswa untuk meningkatkan kesadaran para siswa terhadap penyakit Covid-19 dan langkah-langkah pencegahannya.

scholarly journals The Pandemic Hits Us Hard, but We Don’t Lose Hope

2021 ◽  
Vol 2 (1) ◽  
pp. 1-4
Author(s):  
Krisna Yuarno Phatama ◽  
Sholahuddin Rhatomy, MD ◽  
Asep Santoso ◽  
Nicolaas C. Budhiparama
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Severe Acute Respiratory Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
World Health Organization ◽  
Distress Syndrome ◽  
World Health ◽  
Global Pandemic ◽  
New Variant ◽  
Health Organization

At the end of 2019, we faced a new variant of the coronavirus that can cause pneumonia and acute respiratory distress syndrome-like symptoms. It started in Wuhan, Hubei Province, China, and spread quickly to the whole world.This new virus is called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and can manifest as a disease called coronavirus disease 2019 (COVID-19). On March 13th, 2020 World Health Organization (WHO) declared COVID-19 as a global pandemic, and the story of frightening pandemic begin.

scholarly journals SARS-CoV-2 receptor mutation in Egyptian population

2020 ◽  
Author(s):  
Mohamed M Hafez ◽  
Zeinab K Hassan ◽  
Abeer A. Bahnasy ◽  
Ola S. Ahmed ◽  
Mohamed Abouelhoda ◽  
...  
Keyword(s):  
Infectious Disease ◽  
Acute Respiratory Distress Syndrome ◽  
Severe Acute Respiratory Syndrome ◽  
Respiratory Tract ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
Severe Pneumonia ◽  
Viral Receptor ◽  
Egyptian Population

AbstractThe Coronavirus disease 2019 (COVID-19) is a respiratory tract infectious disease caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 triggers severe pneumonia leading to acute respiratory distress syndrome and death in severe cases. According to WHO reported, Egypt is among the countries with low confirmed SARS CoV2 infected symptomatic cases and death. We postulate that one of the reasons for this may be due mutations in the viral receptor. Therefore this study was conducted to confirm or reject this postulation.

Surfactant therapy in combination treatment of COVID-19 related acute respiratory distress syndrome

2021 ◽  
pp. 50-56
Author(s):  
Renat R. Gubaidullin ◽  
◽  
Aleksandr P. Kuzin ◽  
Vladimir V. Kulakov ◽  
◽  
...  
Keyword(s):  
Mechanical Ventilation ◽  
Acute Respiratory Distress Syndrome ◽  
Respiratory Failure ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Standard Therapy ◽  
Distress Syndrome ◽  
Severe Pneumonia ◽  
Lung Ventilation ◽  
Surfactant Therapy

ntroduction. The COVID-19 pandemic caused an outbreak of viral lung infections with severe acute respiratory syndrome complicated with acute respiratory failure. Despite the fact that the pandemic has a lengthened run, none of the therapeutic approaches have proved to be sufficiently effective according to the evidence-based criteria. We consider the use of surfactant therapy in patients with severe viral pneumonia and acute respiratory distress syndrome (ARDS) as one of the possible methods for treating COVID-19 related pneumonia. Objective. To prove the clinical efficacy and safety of orally inhaled Surfactant-BL, an authorized drug, in the combination therapy of COVID-19 related ARDS. Materials and methods. A total of 38 patients with COVID-19 related severe pneumonia and ARDS were enrolled in the study. Of these, 20 patients received the standard therapy in accordance with the temporary guidelines for the prevention, diagnosis and treatment of the novel coronavirus infection (COVID-19) of the Ministry of Health of the Russian Federation, version 9. And 18 patients received the surfactant therapy in addition to the standard therapy. Surfactant-BL was used in accordance with the instructions on how to administer the drug for the indication – prevention of the development of acute respiratory distress syndrome. A step-by-step approach to the build-up of the respiratory therapy aggressiveness was used to manage hypoxia. We used oxygen inhalation via a face mask with an oxygen inflow of 5–15 l/min, highflow oxygen therapy via nasal cannulas using Airvo 2 devices, non-invasive lung ventilation, invasive lung ventilation in accordance with the principles of protective mechanical ventilation. Results and discussion. Significant differences in the frequency of transfers to mechanical ventilation, mortality, Intensive Care Unit (ICU) and hospitalization length of stay (p <0.05) were found between the groups. Patients receiving surfactant therapy who required a transfer to mechanical ventilation accounted for 22% of cases, and the mortality rate was 16%. In the group of patients receiving standard therapy without surfactant inhalation 45% were transferred to mechanical ventilation, and 35% died. For patients receiving surfactant therapy, the hospital stay was reduced by 20% on average, and ICU stay by 30%. Conclusion. The inclusion of surfactant therapy in the treatment of COVID-19 related severe pneumonia and ARDS can reduce the progression of respiratory failure, avoid the use of mechanical ventilation, shorten the ICU and hospitalization length of stay, and improve the survival rate of this patient cohort.

Cytokine storm syndrome in SARS-CoV-2: a review

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Braira Wahid ◽  
Noshaba Rani ◽  
Muhammad Idrees
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Respiratory Failure ◽  
Severe Acute Respiratory Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
Cytokine Storm ◽  
Global Level ◽  
Management Option ◽  
Human Contact

Abstract After wreaking havoc on a global level with a total of 5,488,825 confirmed cases and 349,095 deaths as of May 2020, severe acute respiratory syndrome coronavirus 2 is truly living up to the expectations of a 21st-century pandemic. Since the major cause of mortality is a respiratory failure from acute respiratory distress syndrome, the only present-day management option is supportive as the transmission relies solely on human-to-human contact. Patients suffering from coronavirus disease 2019 (COVID-19) should be tested for hyper inflammation to screen those for whom immunosuppression can increases chances of survival. As more and more clinical data surfaces, it suggests patients with mild or severe cytokine storms are at greater risk of failing fatally and hence these cytokine storms should be targets for treatment in salvaging COVID-19 patients.

COVID 19 and its management

2021 ◽  
pp. 117-121
Author(s):  
Subhashis Debnath ◽  
Runa Chakravorty ◽  
Donita Devi
Keyword(s):  
Public Health ◽  
Acute Respiratory Distress Syndrome ◽  
Middle East ◽  
Severe Acute Respiratory Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
The Elderly ◽  
Public Health Emergency ◽  
Novel Coronavirus

In December 2019, severe acute respiratory syndrome-coronavirus-2, a novel coronavirus, initiated an outbreak of pneumonia from Wuhan in China, which rapidly spread worldwide. The outbreak was declared as “a public health emergency of international concern” by the WHO on January 30, 2020, and as a pandemic on March 11, 2020. The disease is transmitted by inhalation or contact with infected droplets and the incubation period ranges from 2 to 14 d. The symptoms are usually fever, cough, sore throat, breathlessness, fatigue, malaise among others. The disease is mild in most people; in some (usually the elderly and those with comorbidities), it may progress to pneumonia, acute respiratory distress syndrome (ARDS) and multi organ dysfunction. Many people are asymptomatic. The virus spreads faster than its two ancestors the SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), but has lower fatality.

scholarly journals Early Upregulation of Acute Respiratory Distress Syndrome-Associated Cytokines Promotes Lethal Disease in an Aged-Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Infection

2009 ◽  
Vol 83 (14) ◽  
pp. 7062-7074 ◽  
Author(s):  
Barry Rockx ◽  
Tracey Baas ◽  
Gregory A. Zornetzer ◽  
Bart Haagmans ◽  
Timothy Sheahan ◽  
...  
Keyword(s):  
Immune Response ◽  
Acute Respiratory Distress Syndrome ◽  
Severe Acute Respiratory Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Host Response ◽  
Molecular Mechanisms ◽  
Distress Syndrome ◽  
Aged Mice ◽  
Young Mice

ABSTRACT Several respiratory viruses, including influenza virus and severe acute respiratory syndrome coronavirus (SARS-CoV), produce more severe disease in the elderly, yet the molecular mechanisms governing age-related susceptibility remain poorly studied. Advanced age was significantly associated with increased SARS-related deaths, primarily due to the onset of early- and late-stage acute respiratory distress syndrome (ARDS) and pulmonary fibrosis. Infection of aged, but not young, mice with recombinant viruses bearing spike glycoproteins derived from early human or palm civet isolates resulted in death accompanied by pathological changes associated with ARDS. In aged mice, a greater number of differentially expressed genes were observed than in young mice, whose responses were significantly delayed. Differences between lethal and nonlethal virus phenotypes in aged mice could be attributed to differences in host response kinetics rather than virus kinetics. SARS-CoV infection induced a range of interferon, cytokine, and pulmonary wound-healing genes, as well as several genes associated with the onset of ARDS. Mice that died also showed unique transcriptional profiles of immune response, apoptosis, cell cycle control, and stress. Cytokines associated with ARDS were significantly upregulated in animals experiencing lung pathology and lethal disease, while the same animals experienced downregulation of the ACE2 receptor. These data suggest that the magnitude and kinetics of a disproportionately strong host innate immune response contributed to severe respiratory stress and lethality. Although the molecular mechanisms governing ARDS pathophysiology remain unknown in aged animals, these studies reveal a strategy for dissecting the genetic pathways by which SARS-CoV infection induces changes in the host response, leading to death.

Sign in / Sign up

Export Citation Format

Share Document